Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
AACR Annual Meeting 2026 · San Diego, CA
200 shown of 8,161 total abstracts
  1. Abstract 40442026-04-05 · 20:45 CT · S406
    Quality of life outcomes with Opdivo in patients with HCC
    S. Tolaney, P. Schmid, H. Borghaei, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionGastrointestinal Cancer📄🖼️
  2. Abstract 17352026-04-01 · 18:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-797 study)
    M.C. Garassino, A. Spira · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  3. Abstract 15832026-04-04 · 21:15 CT · S100A
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-736
    C. Saura, S. Modi, M. Reck · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  4. Abstract 99252026-04-04 · 13:15 CT · E450
    Quality of life outcomes with Keytruda in patients with NSCLC
    M.C. Garassino, J. Brahmer, P. Schmid, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  5. Abstract 13932026-04-02 · 19:00 CT · Arie Crown Theater
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-919
    J. Cortes, G. Curigliano · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  6. Abstract 11312026-04-02 · 14:30 CT · Arie Crown Theater
    MONALEESA-675: Kisqali (ribociclib) 2L in HR+ breast cancer
    S. Tolaney, J. Cortes · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  7. Abstract 49772026-04-01 · 20:45 CT · Hall B1
    Quality of life outcomes with Imfinzi in patients with biliary tract
    S. Peters, J. Cortes, L. Paz-Ares, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGastrointestinal Cancer📄🖼️
  8. Abstract 95872026-04-03 · 16:15 CT · Arie Crown Theater
    Quality of life outcomes with Imfinzi in patients with NSCLC
    S. Peters, P. Schmid · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  9. Abstract 99682026-04-04 · 19:30 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-16 study)
    A. Spira, M. Reck, G. Curigliano, et al. · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  10. Abstract 98862026-04-04 · 15:45 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-620
    R. Herbst, J. Brahmer, F. Andre · Institut Gustave Roussy
    Poster SessionLung Cancer—Small Cell📄🖼️
  11. Abstract 16012026-04-04 · 19:45 CT · S100A
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-475 study)
    H. Borghaei, C. Saura · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  12. Abstract 98712026-04-03 · 16:30 CT · Arie Crown Theater
    Quality of life outcomes with Opdivo in patients with NSCLC
    J. Brahmer, N. Rizvi, E. Winer, et al. · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  13. Abstract 17122026-04-02 · 15:00 CT · E450
    PALOMA-515: Ibrance (palbociclib) 2L in HR+ breast cancer
    S. Antonia, M. Krop · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  14. Abstract 10292026-04-04 · 21:15 CT · Arie Crown Theater
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    G. Curigliano, L. Paz-Ares, S. Modi, et al. · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  15. Abstract 19302026-04-01 · 18:00 CT · Hall B1
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    R. Herbst, C. Saura, S. Tolaney, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  16. Abstract 10652026-04-03 · 19:45 CT · S100A
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-691
    P. Schmid, G. Curigliano, R. Herbst · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  17. Abstract 15402026-04-05 · 18:30 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-271
    H. Borghaei, A. Spira · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  18. Abstract 68352026-04-02 · 16:45 CT · Hall B1
    Real-world effectiveness of Opdivo vs standard of care in RCC
    R. Herbst, N. Rizvi, M. Krop, et al. · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  19. Abstract 95852026-04-03 · 16:45 CT · S100A
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    H. Rugo, C. Robert · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  20. Abstract 58142026-04-03 · 20:30 CT · S100A
    Long-term follow-up of Lynparza 2L for ovarian: OlympiA-278
    C. Robert, J. Cortes, R. Herbst · Institut Gustave Roussy
    Poster SessionGynecologic Cancer📄🖼️
  21. Abstract 18142026-04-02 · 21:15 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-669
    J. Cortes, L. Paz-Ares, H. Borghaei, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  22. Abstract 92832026-04-05 · 19:30 CT · S100A
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-898
    F. Andre, S. Antonia, S. Peters, et al. · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  23. Abstract 40812026-04-05 · 13:00 CT · Hall B1
    Quality of life outcomes with Tecentriq in patients with HCC
    S. Modi, S. Peters · Cleveland Clinic
    Poster SessionGastrointestinal Cancer📄🖼️
  24. Abstract 99782026-04-03 · 15:30 CT · S100A
    Long-term follow-up of Keytruda 2L for metastatic melanoma: KEYNOTE-963
    S. Tolaney, H. Rugo, J. Cortes, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionMelanoma📄🖼️
  25. Abstract 18672026-04-05 · 13:15 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-137
    S. Tolaney, M. Reck, J. Brahmer, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  26. Abstract 19942026-04-02 · 14:30 CT · S406
    Quality of life outcomes with Tecentriq in patients with TNBC
    S. Antonia, F. Andre · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  27. Abstract 15862026-04-02 · 19:00 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-994
    A. Spira, M. Reck, H. Rugo, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  28. Abstract 96862026-04-05 · 14:00 CT · Hall B1
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-791
    T. Mok, S. Peters, F. Andre, et al. · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  29. Abstract 14702026-04-01 · 14:00 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-480
    R. Herbst, L. Paz-Ares · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  30. Abstract 98892026-04-04 · 14:30 CT · Arie Crown Theater
    CheckMate-466: Opdivo (nivolumab) 3L+ in NSCLC
    S. Peters, C. Saura, R. Herbst, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  31. Abstract 12882026-04-05 · 19:30 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-199
    S. Peters, P. Schmid, M.C. Garassino, et al. · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  32. Abstract 13342026-04-01 · 14:30 CT · S406
    DESTINY-Breast-435: Enhertu (trastuzumab deruxtecan) adjuvant in HR+ breast cancer
    P. Schmid, L. Paz-Ares, M. Reck · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  33. Abstract 100142026-04-05 · 21:00 CT · Arie Crown Theater
    Long-term follow-up of Keytruda 2L for metastatic melanoma: KEYNOTE-170
    J. Cortes, R. Herbst, H. Rugo, et al. · Chinese University of Hong Kong
    Poster SessionMelanoma📄🖼️
  34. Abstract 13482026-04-02 · 19:00 CT · E450
    MONARCH-90: Verzenio (abemaciclib) 2L in HR+ breast cancer
    H. Rugo, T. Mok · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  35. Abstract 63702026-04-02 · 14:15 CT · S406
    Long-term follow-up of Opdivo 1L for RCC: CheckMate-610
    M. Reck, H. Rugo, E. Winer, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  36. Abstract 42152026-04-05 · 15:15 CT · E450
    PACIFIC-688: Imfinzi (durvalumab) adjuvant in biliary tract
    T. Mok, R. Herbst, S. Modi · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGastrointestinal Cancer📄🖼️
  37. Abstract 96182026-04-05 · 16:45 CT · S100A
    Real-world effectiveness of Imfinzi vs standard of care in NSCLC
    G. Curigliano, F. Andre, A. Spira · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  38. Abstract 46422026-04-04 · 18:00 CT · S406
    CheckMate-782: Opdivo (nivolumab) 2L in HCC
    R. Herbst, C. Robert · University of Chicago
    Poster SessionGastrointestinal Cancer📄🖼️
  39. Abstract 16592026-04-03 · 18:45 CT · S100A
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-927
    R. Herbst, G. Curigliano, H. Borghaei, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  40. Abstract 94292026-04-01 · 21:00 CT · E450
    Long-term follow-up of Tecentriq adjuvant for NSCLC: IMpower-826
    S. Antonia, M. Reck, S. Tolaney, et al. · Institut Gustave Roussy
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  41. Abstract 64712026-04-02 · 15:45 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-474
    S. Modi, R. Herbst, G. Curigliano, et al. · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  42. Abstract 13562026-04-04 · 18:15 CT · Arie Crown Theater
    MONALEESA-193: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    M.C. Garassino, C. Robert, T. Mok, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  43. Abstract 14842026-04-04 · 15:45 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-321 study)
    C. Robert, H. Borghaei · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  44. Abstract 16332026-04-01 · 18:30 CT · Hall B1
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-611
    N. Rizvi, S. Antonia, J. Cortes, et al. · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  45. Abstract 13712026-04-04 · 20:30 CT · Arie Crown Theater
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-314
    M. Reck, S. Peters · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  46. Abstract 47442026-04-02 · 21:00 CT · Hall B1
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-332
    S. Tolaney, S. Peters, C. Robert, et al. · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  47. Abstract 97742026-04-02 · 19:00 CT · S100A
    PACIFIC-838: Imfinzi (durvalumab) maintenance in NSCLC
    P. Schmid, G. Curigliano · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  48. Abstract 45632026-04-02 · 18:30 CT · S406
    Real-world effectiveness of Trodelvy vs standard of care in urothelial carcinoma
    M. Krop, S. Modi, H. Borghaei · Karolinska Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  49. Abstract 10582026-04-02 · 20:30 CT · S100A
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-554
    S. Modi, C. Robert, F. Andre, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  50. Abstract 15992026-04-03 · 16:45 CT · Arie Crown Theater
    Quality of life outcomes with Trodelvy in patients with TNBC
    C. Robert, M.C. Garassino, E. Winer, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  51. Abstract 93532026-04-04 · 16:30 CT · Arie Crown Theater
    Long-term follow-up of Imfinzi maintenance for SCLC: PACIFIC-973
    R. Herbst, P. Schmid · MD Anderson Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  52. Abstract 99562026-04-05 · 21:15 CT · S406
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-416 study)
    J. Cortes, S. Antonia, R. Herbst, et al. · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  53. Abstract 12112026-04-02 · 13:30 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-927
    H. Borghaei, C. Robert, N. Rizvi, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  54. Abstract 60192026-04-03 · 19:00 CT · E450
    CheckMate-250: Opdivo (nivolumab) 2L in RCC
    C. Saura, L. Paz-Ares, S. Antonia · Mayo Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  55. Abstract 99622026-04-02 · 13:15 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-971
    C. Robert, J. Brahmer, S. Modi, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  56. Abstract 12512026-04-03 · 21:00 CT · S100A
    Real-world effectiveness of Keytruda vs standard of care in TNBC
    E. Winer, J. Cortes · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  57. Abstract 13842026-04-03 · 13:30 CT · Hall B1
    MONALEESA-407: Kisqali (ribociclib) maintenance in HR+ breast cancer
    A. Spira, T. Mok · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  58. Abstract 42692026-04-03 · 14:00 CT · E450
    ASCENT-924: Trodelvy (sacituzumab govitecan) 3L+ in urothelial carcinoma
    N. Rizvi, G. Curigliano, S. Tolaney · Memorial Sloan Kettering Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  59. Abstract 99022026-04-01 · 19:15 CT · S100A
    Long-term follow-up of Tagrisso 3L+ for NSCLC: FLAURA-57
    F. Andre, C. Robert, H. Borghaei, et al. · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  60. Abstract 47752026-04-02 · 13:45 CT · Arie Crown Theater
    DESTINY-Breast-388: Enhertu (trastuzumab deruxtecan) 3L+ in gastric
    F. Andre, C. Saura, N. Rizvi, et al. · Stanford Cancer Institute
    Poster SessionGastrointestinal Cancer📄🖼️
  61. Abstract 91242026-04-05 · 19:30 CT · E450
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-963
    J. Brahmer, E. Winer, H. Borghaei, et al. · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  62. Abstract 47262026-04-04 · 16:45 CT · E450
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-563 study)
    S. Tolaney, C. Robert · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  63. Abstract 42722026-04-01 · 16:45 CT · S406
    Enhertu plus chemotherapy in previously untreated gastric: updated analysis from DESTINY-Breast-75
    P. Schmid, G. Curigliano, A. Spira, et al. · Institut Gustave Roussy
    Poster SessionGastrointestinal Cancer📄🖼️
  64. Abstract 10652026-04-03 · 18:15 CT · S406
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    N. Rizvi, T. Mok, F. Andre · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  65. Abstract 10292026-04-03 · 20:15 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-537 study)
    M.C. Garassino, E. Winer, J. Cortes · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  66. Abstract 91772026-04-05 · 14:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-851 study)
    J. Cortes, C. Robert, M. Reck · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  67. Abstract 16012026-04-01 · 16:45 CT · Arie Crown Theater
    MONARCH-178: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    H. Borghaei, G. Curigliano · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  68. Abstract 44442026-04-03 · 18:30 CT · S406
    Quality of life outcomes with Padcev in patients with urothelial carcinoma
    R. Herbst, C. Robert, S. Antonia, et al. · Karolinska Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  69. Abstract 15942026-04-02 · 13:15 CT · E450
    Long-term follow-up of Trodelvy neoadjuvant for TNBC: ASCENT-587
    L. Paz-Ares, R. Herbst · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  70. Abstract 56142026-04-01 · 14:30 CT · E450
    Quality of life outcomes with Lynparza in patients with ovarian
    J. Brahmer, T. Mok, S. Tolaney · Institut Gustave Roussy
    Poster SessionGynecologic Cancer📄🖼️
  71. Abstract 16592026-04-03 · 18:45 CT · S406
    Long-term follow-up of Trodelvy maintenance for TNBC: ASCENT-557
    S. Peters, C. Robert, J. Cortes, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  72. Abstract 11712026-04-05 · 14:00 CT · S100A
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    H. Rugo, H. Borghaei, L. Paz-Ares, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  73. Abstract 49562026-04-05 · 18:15 CT · Arie Crown Theater
    DESTINY-Breast-864: Enhertu (trastuzumab deruxtecan) maintenance in gastric
    S. Tolaney, C. Saura, S. Peters, et al. · Institut Gustave Roussy
    Poster SessionGastrointestinal Cancer📄🖼️
  74. Abstract 64642026-04-04 · 14:45 CT · S100A
    Real-world effectiveness of Lynparza vs standard of care in ovarian
    R. Herbst, N. Rizvi · University of Chicago
    Poster SessionGynecologic Cancer📄🖼️
  75. Abstract 42182026-04-04 · 16:45 CT · S406
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-363 study)
    N. Rizvi, J. Brahmer · Mayo Clinic
    Poster SessionGastrointestinal Cancer📄🖼️
  76. Abstract 48402026-04-02 · 20:15 CT · S100A
    Real-world effectiveness of Tecentriq vs standard of care in HCC
    R. Herbst, S. Tolaney · Institut Gustave Roussy
    Poster SessionGastrointestinal Cancer📄🖼️
  77. Abstract 100842026-04-03 · 16:15 CT · S406
    Real-world effectiveness of Keytruda vs standard of care in metastatic melanoma
    M.C. Garassino, C. Robert, R. Herbst, et al. · Karolinska Institute
    Poster SessionMelanoma📄🖼️
  78. Abstract 51612026-04-04 · 14:30 CT · E450
    Lynparza plus chemotherapy in previously untreated prostate: updated analysis from OlympiA-586
    M. Reck, A. Spira, L. Paz-Ares, et al. · MD Anderson Cancer Center
    Poster SessionGenitourinary Cancer—Prostate📄🖼️
  79. Abstract 41902026-04-02 · 14:15 CT · Hall B1
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-107 study)
    A. Spira, H. Borghaei, E. Winer, et al. · Chinese University of Hong Kong
    Poster SessionGastrointestinal Cancer📄🖼️
  80. Abstract 95222026-04-01 · 16:00 CT · Arie Crown Theater
    Long-term follow-up of Keytruda neoadjuvant for metastatic melanoma: KEYNOTE-879
    J. Cortes, H. Rugo · Institut Gustave Roussy
    Poster SessionMelanoma📄🖼️
  81. Abstract 60502026-04-01 · 14:15 CT · S100A
    Long-term follow-up of Lynparza maintenance for ovarian: OlympiA-905
    P. Schmid, L. Paz-Ares, S. Modi, et al. · Dana-Farber Cancer Institute
    Poster SessionGynecologic Cancer📄🖼️
  82. Abstract 94442026-04-01 · 14:00 CT · Hall B1
    Real-world effectiveness of Imfinzi vs standard of care in SCLC
    G. Curigliano, J. Brahmer · Cleveland Clinic
    Poster SessionLung Cancer—Small Cell📄🖼️
  83. Abstract 11382026-04-01 · 15:45 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-573 study)
    M. Krop, T. Mok · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  84. Abstract 96932026-04-03 · 19:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-624 study)
    M.C. Garassino, A. Spira · Karolinska Institute
    Poster SessionLung Cancer—Small Cell📄🖼️
  85. Abstract 69622026-04-03 · 14:00 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-926
    S. Modi, H. Borghaei, J. Brahmer, et al. · Mayo Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  86. Abstract 18432026-04-03 · 15:15 CT · E450
    Quality of life outcomes with Keytruda in patients with TNBC
    A. Spira, C. Saura · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  87. Abstract 94572026-04-03 · 13:45 CT · Hall B1
    Real-world effectiveness of Opdivo vs standard of care in NSCLC
    P. Schmid, H. Borghaei, S. Peters, et al. · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  88. Abstract 10752026-04-03 · 21:15 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-751
    N. Rizvi, J. Brahmer, A. Spira, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  89. Abstract 13942026-04-03 · 13:45 CT · S406
    Long-term follow-up of Trodelvy 2L for TNBC: ASCENT-838
    J. Cortes, C. Saura, P. Schmid · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  90. Abstract 101422026-04-01 · 21:15 CT · Hall B1
    KEYNOTE-309: Keytruda (pembrolizumab) neoadjuvant in metastatic melanoma
    M. Reck, E. Winer, S. Antonia, et al. · Princess Margaret Cancer Centre
    Poster SessionMelanoma📄🖼️
  91. Abstract 42482026-04-01 · 21:30 CT · S100A
    Quality of life outcomes with Enhertu in patients with gastric
    N. Rizvi, H. Rugo, S. Modi, et al. · Dana-Farber Cancer Institute
    Poster SessionGastrointestinal Cancer📄🖼️
  92. Abstract 14532026-04-02 · 16:15 CT · E450
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-833
    F. Andre, M. Reck · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  93. Abstract 98872026-04-03 · 13:30 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-360 study)
    M. Reck, E. Winer, A. Spira · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  94. Abstract 10092026-04-05 · 15:30 CT · Hall B1
    ASCENT-6: Trodelvy (sacituzumab govitecan) 3L+ in TNBC
    G. Curigliano, S. Modi, M.C. Garassino, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  95. Abstract 15082026-04-02 · 21:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-23 study)
    S. Antonia, P. Schmid · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  96. Abstract 11992026-04-04 · 15:30 CT · Arie Crown Theater
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-14
    M. Krop, L. Paz-Ares · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  97. Abstract 48522026-04-04 · 20:15 CT · S100A
    Long-term follow-up of Tecentriq 3L+ for HCC: IMpower-994
    H. Borghaei, F. Andre, R. Herbst · Dana-Farber Cancer Institute
    Poster SessionGastrointestinal Cancer📄🖼️
  98. Abstract 99992026-04-05 · 19:00 CT · S100A
    DESTINY-Breast-183: Enhertu (trastuzumab deruxtecan) maintenance in NSCLC
    G. Curigliano, L. Paz-Ares, R. Herbst · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  99. Abstract 90572026-04-04 · 19:45 CT · S100A
    Real-world effectiveness of Keytruda vs standard of care in NSCLC
    H. Borghaei, P. Schmid, C. Saura · Institut Gustave Roussy
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  100. Abstract 55522026-04-05 · 13:30 CT · S100A
    Lynparza plus chemotherapy in previously untreated ovarian: updated analysis from OlympiA-222
    C. Robert, S. Tolaney, G. Curigliano, et al. · National Cancer Center Japan
    Poster SessionGynecologic Cancer📄🖼️
  101. Abstract 17662026-04-04 · 16:45 CT · S406
    PALOMA-798: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    N. Rizvi, M. Reck, G. Curigliano, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  102. Abstract 99272026-04-01 · 15:15 CT · S406
    Quality of life outcomes with Tecentriq in patients with NSCLC
    S. Modi, P. Schmid, S. Peters, et al. · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  103. Abstract 96602026-04-04 · 18:30 CT · S100A
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-286
    J. Cortes, T. Mok, S. Tolaney, et al. · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  104. Abstract 15012026-04-03 · 20:00 CT · S100A
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    J. Cortes, S. Peters, C. Saura, et al. · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  105. Abstract 95252026-04-01 · 18:30 CT · S406
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-221
    J. Cortes, M. Krop · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  106. Abstract 45032026-04-02 · 18:00 CT · Hall B1
    Long-term follow-up of Enhertu 3L+ for gastric: DESTINY-Breast-863
    S. Peters, P. Schmid, H. Rugo, et al. · Mayo Clinic
    Poster SessionGastrointestinal Cancer📄🖼️
  107. Abstract 56962026-04-01 · 13:30 CT · E450
    Biomarker subgroup analysis of Lynparza in prostate (the OlympiA-546 study)
    M. Reck, P. Schmid, A. Spira, et al. · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Prostate📄🖼️
  108. Abstract 18282026-04-03 · 13:30 CT · Hall B1
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    G. Curigliano, C. Robert, M. Krop · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  109. Abstract 63352026-04-04 · 18:00 CT · S100A
    Lynparza plus chemotherapy in previously untreated ovarian: updated analysis from OlympiA-155
    T. Mok, L. Paz-Ares, F. Andre · MD Anderson Cancer Center
    Poster SessionGynecologic Cancer📄🖼️
  110. Abstract 92092026-04-02 · 19:00 CT · S406
    FLAURA-709: Tagrisso (osimertinib) 2L in NSCLC
    T. Mok, M. Reck, R. Herbst, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  111. Abstract 12102026-04-01 · 19:45 CT · S406
    Long-term follow-up of Enhertu 2L for HR+ breast cancer: DESTINY-Breast-760
    E. Winer, S. Antonia, M.C. Garassino, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  112. Abstract 90102026-04-01 · 21:45 CT · E450
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-238
    A. Spira, F. Andre, E. Winer, et al. · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Small Cell📄🖼️
  113. Abstract 10532026-04-03 · 19:15 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-679 study)
    M.C. Garassino, N. Rizvi, H. Borghaei · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  114. Abstract 95542026-04-03 · 21:00 CT · S100A
    Long-term follow-up of Enhertu adjuvant for NSCLC: DESTINY-Breast-139
    H. Rugo, L. Paz-Ares · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  115. Abstract 96882026-04-04 · 20:00 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-834
    F. Andre, M.C. Garassino, G. Curigliano · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  116. Abstract 92612026-04-02 · 16:00 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-339 study)
    G. Curigliano, E. Winer, H. Borghaei · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  117. Abstract 95852026-04-05 · 19:45 CT · E450
    Quality of life outcomes with Imfinzi in patients with SCLC
    H. Rugo, S. Peters, H. Borghaei, et al. · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Small Cell📄🖼️
  118. Abstract 92062026-04-01 · 18:15 CT · E450
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    G. Curigliano, C. Robert, A. Spira, et al. · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  119. Abstract 18442026-04-04 · 21:15 CT · S100A
    MONARCH-271: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    M. Krop, P. Schmid · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  120. Abstract 45752026-04-01 · 14:00 CT · S406
    Long-term follow-up of Padcev 1L for urothelial carcinoma: EV-874
    S. Peters, T. Mok, C. Robert · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  121. Abstract 15662026-04-04 · 20:45 CT · S406
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    H. Borghaei, S. Modi, N. Rizvi · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  122. Abstract 11082026-04-02 · 21:15 CT · E450
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-231
    L. Paz-Ares, R. Herbst, M.C. Garassino, et al. · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  123. Abstract 14272026-04-03 · 18:15 CT · Arie Crown Theater
    ASCENT-271: Trodelvy (sacituzumab govitecan) maintenance in TNBC
    F. Andre, H. Rugo, P. Schmid · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  124. Abstract 98152026-04-05 · 13:15 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-708 study)
    H. Borghaei, C. Saura, G. Curigliano · Mayo Clinic
    Poster SessionMelanoma📄🖼️
  125. Abstract 19492026-04-03 · 16:00 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-190
    J. Brahmer, A. Spira, S. Antonia, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  126. Abstract 48742026-04-02 · 15:15 CT · S406
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-124
    N. Rizvi, S. Peters, J. Brahmer, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  127. Abstract 16272026-04-02 · 19:15 CT · E450
    ASCENT-851: Trodelvy (sacituzumab govitecan) adjuvant in TNBC
    H. Borghaei, S. Peters, H. Rugo, et al. · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  128. Abstract 11332026-04-03 · 16:00 CT · E450
    Long-term follow-up of Keytruda 2L for TNBC: KEYNOTE-488
    H. Borghaei, J. Cortes, M. Krop, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  129. Abstract 95492026-04-03 · 20:45 CT · S100A
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-637
    M.C. Garassino, H. Borghaei, A. Spira · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  130. Abstract 14342026-04-05 · 19:45 CT · E450
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-358
    S. Peters, M. Krop, S. Antonia · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  131. Abstract 47932026-04-04 · 16:15 CT · S406
    Long-term follow-up of Padcev adjuvant for urothelial carcinoma: EV-551
    S. Tolaney, J. Brahmer · Princess Margaret Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  132. Abstract 41052026-04-03 · 19:00 CT · S406
    Biomarker subgroup analysis of Opdivo in HCC (the CheckMate-451 study)
    N. Rizvi, R. Herbst, S. Antonia · Massachusetts General Hospital
    Poster SessionGastrointestinal Cancer📄🖼️
  133. Abstract 97452026-04-02 · 18:30 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-965 study)
    T. Mok, S. Antonia, H. Borghaei · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  134. Abstract 16562026-04-02 · 20:15 CT · S406
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    M.C. Garassino, E. Winer, H. Rugo · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  135. Abstract 44652026-04-05 · 19:15 CT · S406
    Real-world effectiveness of Imfinzi vs standard of care in biliary tract
    S. Modi, T. Mok, M. Krop, et al. · Dana-Farber Cancer Institute
    Poster SessionGastrointestinal Cancer📄🖼️
  136. Abstract 46962026-04-01 · 16:45 CT · S100A
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-166 study)
    H. Borghaei, S. Modi, G. Curigliano, et al. · Mayo Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  137. Abstract 98922026-04-02 · 18:45 CT · E450
    Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-314
    H. Borghaei, L. Paz-Ares, M. Reck, et al. · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  138. Abstract 63432026-04-01 · 18:00 CT · S406
    Real-world effectiveness of Keytruda vs standard of care in RCC
    S. Modi, T. Mok · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  139. Abstract 96382026-04-04 · 16:45 CT · S100A
    Quality of life outcomes with Enhertu in patients with NSCLC
    F. Andre, A. Spira · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  140. Abstract 16172026-04-02 · 15:00 CT · S100A
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-924
    H. Rugo, J. Cortes · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  141. Abstract 14322026-04-01 · 20:15 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-796 study)
    S. Modi, C. Robert, N. Rizvi, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  142. Abstract 41822026-04-03 · 16:15 CT · Hall B1
    ASCENT-348: Trodelvy (sacituzumab govitecan) 2L in urothelial carcinoma
    M.C. Garassino, S. Antonia, E. Winer, et al. · University of Chicago
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  143. Abstract 12132026-04-01 · 14:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-167 study)
    P. Schmid, M.C. Garassino, J. Brahmer, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  144. Abstract 64802026-04-01 · 14:15 CT · Arie Crown Theater
    OlympiA-924: Lynparza (olaparib) neoadjuvant in ovarian
    J. Brahmer, M. Krop, C. Saura, et al. · Mayo Clinic
    Poster SessionGynecologic Cancer📄🖼️
  145. Abstract 41092026-04-01 · 21:30 CT · S100A
    Long-term follow-up of Trodelvy adjuvant for urothelial carcinoma: ASCENT-900
    F. Andre, P. Schmid, C. Robert, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  146. Abstract 93192026-04-03 · 19:45 CT · S100A
    Long-term follow-up of Tecentriq 2L for NSCLC: IMpower-812
    A. Spira, P. Schmid, S. Antonia, et al. · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  147. Abstract 66952026-04-01 · 19:45 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-464
    M.C. Garassino, C. Robert, J. Cortes · Mayo Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  148. Abstract 44512026-04-01 · 14:15 CT · S100A
    Biomarker subgroup analysis of Enhertu in gastric (the DESTINY-Breast-994 study)
    L. Paz-Ares, N. Rizvi, C. Saura, et al. · Peter MacCallum Cancer Centre
    Poster SessionGastrointestinal Cancer📄🖼️
  149. Abstract 41772026-04-05 · 13:30 CT · S406
    Long-term follow-up of Padcev 1L for urothelial carcinoma: EV-293
    M. Reck, T. Mok · Princess Margaret Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  150. Abstract 98992026-04-04 · 20:15 CT · S406
    Quality of life outcomes with Tagrisso in patients with NSCLC
    S. Peters, A. Spira, F. Andre · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  151. Abstract 98272026-04-02 · 20:00 CT · S406
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-783
    M.C. Garassino, S. Tolaney, T. Mok, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  152. Abstract 40892026-04-02 · 21:00 CT · Arie Crown Theater
    Long-term follow-up of Padcev 3L+ for urothelial carcinoma: EV-709
    M. Krop, S. Modi · Cleveland Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  153. Abstract 60802026-04-01 · 19:45 CT · S406
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-404 study)
    A. Spira, E. Winer, M.C. Garassino, et al. · Massachusetts General Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  154. Abstract 13042026-04-04 · 14:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-395 study)
    C. Robert, P. Schmid · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  155. Abstract 95352026-04-03 · 20:30 CT · S100A
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-867
    H. Borghaei, N. Rizvi · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  156. Abstract 46622026-04-01 · 13:45 CT · S100A
    Long-term follow-up of Imfinzi 3L+ for biliary tract: PACIFIC-655
    J. Brahmer, L. Paz-Ares, E. Winer · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGastrointestinal Cancer📄🖼️
  157. Abstract 15502026-04-02 · 16:15 CT · S406
    MONARCH-840: Verzenio (abemaciclib) adjuvant in HR+ breast cancer
    S. Modi, L. Paz-Ares, S. Antonia · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  158. Abstract 12962026-04-05 · 21:30 CT · S406
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    P. Schmid, N. Rizvi, A. Spira, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  159. Abstract 93282026-04-04 · 16:15 CT · S406
    FLAURA-951: Tagrisso (osimertinib) 3L+ in NSCLC
    T. Mok, N. Rizvi, S. Peters · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  160. Abstract 44122026-04-01 · 14:00 CT · Hall B1
    Long-term follow-up of Trodelvy adjuvant for urothelial carcinoma: ASCENT-99
    L. Paz-Ares, M. Reck · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  161. Abstract 14962026-04-01 · 18:00 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-583
    E. Winer, G. Curigliano, A. Spira, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  162. Abstract 48232026-04-01 · 19:30 CT · S406
    ASCENT-857: Trodelvy (sacituzumab govitecan) 1L in urothelial carcinoma
    R. Herbst, S. Antonia, S. Tolaney, et al. · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  163. Abstract 93672026-04-05 · 19:00 CT · S100A
    PACIFIC-813: Imfinzi (durvalumab) 1L in NSCLC
    C. Robert, L. Paz-Ares, E. Winer, et al. · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  164. Abstract 15062026-04-02 · 18:00 CT · Arie Crown Theater
    PALOMA-845: Ibrance (palbociclib) 1L in HR+ breast cancer
    N. Rizvi, S. Tolaney · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  165. Abstract 42052026-04-03 · 15:00 CT · S100A
    Enhertu plus chemotherapy in previously untreated gastric: updated analysis from DESTINY-Breast-953
    P. Schmid, A. Spira, R. Herbst, et al. · Princess Margaret Cancer Centre
    Poster SessionGastrointestinal Cancer📄🖼️
  166. Abstract 13062026-04-03 · 20:30 CT · E450
    OlympiA-766: Lynparza (olaparib) adjuvant in HR+ breast cancer
    S. Modi, M. Krop · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  167. Abstract 101612026-04-02 · 16:30 CT · E450
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-510
    M.C. Garassino, N. Rizvi, C. Saura, et al. · Cleveland Clinic
    Poster SessionMelanoma📄🖼️
  168. Abstract 47472026-04-02 · 21:30 CT · Hall B1
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-353 study)
    N. Rizvi, R. Herbst, M.C. Garassino, et al. · Dana-Farber Cancer Institute
    Poster SessionGastrointestinal Cancer📄🖼️
  169. Abstract 16252026-04-05 · 18:30 CT · S406
    MONARCH-982: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    S. Peters, C. Saura, M. Krop · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  170. Abstract 98722026-04-05 · 15:45 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-873 study)
    L. Paz-Ares, S. Modi, C. Robert · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  171. Abstract 98732026-04-01 · 16:45 CT · S406
    Long-term follow-up of Enhertu neoadjuvant for NSCLC: DESTINY-Breast-81
    N. Rizvi, H. Borghaei, S. Peters, et al. · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  172. Abstract 17992026-04-03 · 13:45 CT · Hall B1
    Long-term follow-up of Trodelvy 1L for TNBC: ASCENT-848
    S. Antonia, J. Brahmer, L. Paz-Ares, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  173. Abstract 45822026-04-04 · 18:15 CT · S406
    Quality of life outcomes with Trodelvy in patients with urothelial carcinoma
    H. Borghaei, H. Rugo, T. Mok · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  174. Abstract 49772026-04-01 · 20:30 CT · E450
    Real-world effectiveness of Padcev vs standard of care in urothelial carcinoma
    P. Schmid, M.C. Garassino, E. Winer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  175. Abstract 43622026-04-02 · 20:15 CT · S406
    Real-world effectiveness of Enhertu vs standard of care in gastric
    H. Borghaei, R. Herbst, H. Rugo, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionGastrointestinal Cancer📄🖼️
  176. Abstract 62722026-04-03 · 19:00 CT · S100A
    Long-term follow-up of Lynparza 3L+ for ovarian: OlympiA-670
    R. Herbst, P. Schmid, H. Borghaei, et al. · Massachusetts General Hospital
    Poster SessionGynecologic Cancer📄🖼️
  177. Abstract 16752026-04-05 · 15:00 CT · S100A
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    H. Borghaei, G. Curigliano, R. Herbst, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  178. Abstract 13042026-04-04 · 21:00 CT · E450
    Long-term follow-up of Keytruda neoadjuvant for TNBC: KEYNOTE-276
    H. Rugo, F. Andre · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  179. Abstract 17572026-04-03 · 21:45 CT · S100A
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-410
    M. Krop, J. Brahmer, C. Saura · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  180. Abstract 42782026-04-05 · 20:00 CT · Arie Crown Theater
    DESTINY-Breast-981: Enhertu (trastuzumab deruxtecan) maintenance in gastric
    J. Brahmer, G. Curigliano, S. Tolaney · University of Chicago
    Poster SessionGastrointestinal Cancer📄🖼️
  181. Abstract 18852026-04-04 · 14:45 CT · Hall B1
    ASCENT-755: Trodelvy (sacituzumab govitecan) 1L in TNBC
    L. Paz-Ares, R. Herbst · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  182. Abstract 55582026-04-05 · 14:30 CT · E450
    Real-world effectiveness of Lynparza vs standard of care in prostate
    S. Modi, L. Paz-Ares, J. Brahmer · Memorial Sloan Kettering Cancer Center
    Poster SessionGenitourinary Cancer—Prostate📄🖼️
  183. Abstract 45812026-04-01 · 14:00 CT · S406
    CheckMate-373: Opdivo (nivolumab) 3L+ in HCC
    J. Cortes, M. Krop · Dana-Farber Cancer Institute
    Poster SessionGastrointestinal Cancer📄🖼️
  184. Abstract 17062026-04-05 · 16:00 CT · E450
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-570 study)
    S. Tolaney, M.C. Garassino, J. Brahmer, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  185. Abstract 41612026-04-01 · 19:15 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated biliary tract: updated analysis from PACIFIC-552
    E. Winer, T. Mok, C. Robert, et al. · Stanford Cancer Institute
    Poster SessionGastrointestinal Cancer📄🖼️
  186. Abstract 18462026-04-02 · 18:15 CT · Arie Crown Theater
    MONALEESA-992: Kisqali (ribociclib) 1L in HR+ breast cancer
    A. Spira, C. Robert, S. Peters, et al. · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  187. Abstract 17792026-04-04 · 18:45 CT · Hall B1
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-966
    S. Antonia, C. Robert, E. Winer, et al. · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  188. Abstract 11272026-04-02 · 15:30 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-189 study)
    M. Reck, S. Antonia, P. Schmid, et al. · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  189. Abstract 10682026-04-02 · 20:45 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-801
    M. Krop, M.C. Garassino, N. Rizvi, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  190. Abstract 96272026-04-04 · 18:15 CT · S406
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-190 study)
    L. Paz-Ares, S. Antonia, M.C. Garassino · Vall d'Hebron Institute of Oncology
    Poster SessionMelanoma📄🖼️
  191. Abstract 91132026-04-04 · 15:15 CT · Arie Crown Theater
    FLAURA-965: Tagrisso (osimertinib) 2L in NSCLC
    C. Saura, H. Borghaei, H. Rugo, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  192. Abstract 14452026-04-01 · 21:15 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-106 study)
    G. Curigliano, S. Peters, M.C. Garassino, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  193. Abstract 98232026-04-04 · 14:45 CT · Arie Crown Theater
    Long-term follow-up of Opdivo adjuvant for NSCLC: CheckMate-144
    P. Schmid, C. Saura, S. Tolaney, et al. · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  194. Abstract 90232026-04-02 · 18:15 CT · Hall B1
    FLAURA-718: Tagrisso (osimertinib) adjuvant in NSCLC
    N. Rizvi, P. Schmid, S. Antonia, et al. · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  195. Abstract 97442026-04-05 · 13:00 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-453
    T. Mok, N. Rizvi, C. Saura, et al. · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  196. Abstract 16002026-04-03 · 16:15 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-418
    M. Reck, A. Spira · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  197. Abstract 97772026-04-01 · 19:30 CT · S406
    Long-term follow-up of Imfinzi 1L for SCLC: PACIFIC-596
    M.C. Garassino, J. Brahmer, A. Spira, et al. · Cleveland Clinic
    Poster SessionLung Cancer—Small Cell📄🖼️
  198. Abstract 47182026-04-05 · 21:45 CT · S100A
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-284
    S. Peters, L. Paz-Ares, C. Saura · University of Chicago
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  199. Abstract 90032026-04-04 · 15:00 CT · S100A
    Long-term follow-up of Opdivo 1L for NSCLC: CheckMate-194
    T. Mok, M. Krop, S. Tolaney, et al. · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  200. Abstract 42582026-04-01 · 16:30 CT · S406
    Enhertu plus chemotherapy in previously untreated gastric: updated analysis from DESTINY-Breast-121
    C. Robert, H. Borghaei, C. Saura · Stanford Cancer Institute
    Poster SessionGastrointestinal Cancer📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.